Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan—Why Not? is a research paper published in JCO Oncology Practice (2022). On theSindex it has a DataRank of 0.279. It has been cited 4 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0.0371
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 3 citers.
NCI NIH HHS
Grant: P30 CA023108
National Institutes of Health
Grant: 5P30CA023108-40
Cancer Center Support Grant
Fields of Study
MeSH Terms
Keywords